Lista de obras -

A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma

artículo científico publicado en 2017

A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma

artículo científico publicado en 2021

A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma.

artículo científico publicado en 2014

Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma

artículo científico publicado en 2015

An update on the safety and efficacy of regorafenib in the treatment of solid cancers.

artículo científico publicado en 2014

Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade

artículo científico publicado en 2014

Biology and significance of alpha-fetoprotein in hepatocellular carcinoma

scientific article published on 11 September 2019

Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma.

artículo científico publicado en 2012

Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.

artículo científico publicado en 2014

Drug development for hepatocellular carcinoma: knowing the past helps to understand the future

artículo científico publicado en 2014

Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong

scientific article published on 01 March 2014

Embedding of Genes Using Cancer Gene Expression Data: Biological Relevance and Potential Application on Biomarker Discovery

article

Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma ⬇️

artículo científico publicado el 20 de febrero de 2013

Genome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma

scientific article published on 04 February 2019

Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240

scientific article published on 24 November 2020

Hepatotoxicity of targeted therapy for cancer.

artículo científico publicado en 2016

Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.

artículo científico publicado en 2018

Hong Kong consensus recommendations on the management of hepatocellular carcinoma

artículo científico publicado en 2015

ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib

artículo científico publicado en 2018

Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.

artículo científico publicado en 2017

Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective

scientific article published on 01 June 2012

Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade

artículo científico publicado en 2016

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.

artículo científico publicado en 2015

Lymphedema and quality of life in Chinese women after treatment for breast cancer.

artículo científico publicado en 2009

Management of hepatocellular carcinoma: beyond sorafenib.

artículo científico

Misleading chest radiography in a patient with SARS.

artículo científico publicado en 2004

Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials

scientific article published on 01 February 2010

Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing

artículo científico publicado en 2013

Novel systemic therapeutic for nasopharyngeal carcinoma.

artículo científico

PARP inhibition in BRCA-mutated breast and ovarian cancers

artículo científico publicado en 2010

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.

artículo científico publicado en 2011

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

artículo científico publicado en 2018

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.

artículo científico publicado en 2016

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.

artículo científico publicado en 2015

Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma

artículo científico publicado en 2016

Reply to 'Comment on 'Circulating Neutrophils in patients with hepatocellular carcinoma"

artículo científico publicado en 2018

Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

artículo científico publicado en 2016

Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how?

artículo científico publicado en 2013

Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients

scientific article published on 29 April 2019

Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

artículo científico publicado en 2012

Targeted therapy of hepatocellular carcinoma: present and future.

artículo científico

Targeting angiogenic genes as a therapeutic approach for hepatocellular carcinoma

artículo científico publicado en 2015

The association of liver function and quality of life of patients with liver cancer

artículo científico publicado en 2019

Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion

artículo científico publicado en 2017

Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization.

artículo científico

Vitamin E in prevention against hepatocellular carcinoma: right type, right dose and right population

artículo científico publicado en 2012

What do oncologists need to know about biosimilar products?

artículo científico publicado en 2016

Lista de obras de

A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma

A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma

A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma.

Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma

An update on the safety and efficacy of regorafenib in the treatment of solid cancers.

Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade

Biology and significance of alpha-fetoprotein in hepatocellular carcinoma

Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma.

Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.

Drug development for hepatocellular carcinoma: knowing the past helps to understand the future

Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong

Embedding of Genes Using Cancer Gene Expression Data: Biological Relevance and Potential Application on Biomarker Discovery

Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma ⬇️

Genome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma

Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240

Hepatotoxicity of targeted therapy for cancer.

Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.

Hong Kong consensus recommendations on the management of hepatocellular carcinoma

ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib

Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.

Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective

Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.

Lymphedema and quality of life in Chinese women after treatment for breast cancer.

Management of hepatocellular carcinoma: beyond sorafenib.

Misleading chest radiography in a patient with SARS.

Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials

Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing

Novel systemic therapeutic for nasopharyngeal carcinoma.

PARP inhibition in BRCA-mutated breast and ovarian cancers

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.

Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma

Reply to 'Comment on 'Circulating Neutrophils in patients with hepatocellular carcinoma"

Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how?

Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients

Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

Targeted therapy of hepatocellular carcinoma: present and future.

Targeting angiogenic genes as a therapeutic approach for hepatocellular carcinoma

The association of liver function and quality of life of patients with liver cancer

Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion

Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization.

Vitamin E in prevention against hepatocellular carcinoma: right type, right dose and right population

What do oncologists need to know about biosimilar products?